Fig. 6

Senescence signature could predict immune therapy and targeted therapy response. (A) Comparison of senescence signature scores between PD-1 blockade treatment and no treatment group in MC38 cells (Wilcoxon test, P < 0.028). (B) Differences of senescence signature score among different immunotherapy in mammary tumor with BRCA mutation mice (Kruskal-Wallis test, P = 0.00087). (C) The HCC patients with objective response after anti-PD-1/anti-PD-L1-based therapy divided into two groups with or without clinical benefit response. The differences in the proportion of high senescence signature between the two groups were tested by Fisher’s exact test, P = 0.068. (D) After anti-PD-1/anti-PD-L1-based therapy, OS of HCC patients with high senescence signature was worse than those with low senescence signature (log-rank test, P = 0.00071). (E,F) The correlation of senescence signature with drug sensitivity was performed with GDSC drug data in pan-cancer. Blue dots represent the 5 top drugs with a negative correlation and p < 0.05, red dots represent the top 5 drugs with a positive correlation and a p < 0.05.